Tango Therapeutics, Inc. SEC Filings

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC and Chen Yu report beneficial ownership of Tango Therapeutics, Inc. Common Stock. Each reporting person is deemed to beneficially own 10,147,867 shares, representing 7.0% of the class, including 9,081,201 shares of Common Stock and 1,066,666 shares underlying Pre-Funded Warrants exercisable within 60 days. The Pre-Funded Warrants are subject to a 9.99% Beneficial Ownership Limitation, and the reporting persons state that they collectively hold less than this threshold. The percentage is calculated based on 145,714,648 shares of Common Stock, consisting of 144,647,982 shares outstanding as of May 6, 2026 plus the warrant shares assumed exercisable. The reporting persons disclaim group status and beneficial ownership beyond their pecuniary interests.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of common stock of Tango Therapeutics, Inc. on a Schedule 13G. The holding represents 6.0% of Tango’s common stock.

The filing shows shared voting power over 9,740,098.80 shares and shared dispositive power over 9,740,206.80 shares, with an aggregate beneficial ownership of 9,742,402.80 shares. The securities are attributed to Goldman Sachs & Co. LLC as a broker-dealer and investment adviser subsidiary of The Goldman Sachs Group, Inc., which is reporting as a parent holding company. The Goldman Sachs reporting units disclaim beneficial ownership of certain client accounts and investment entities as described in the disclosure.

Woodline Partners LP filed an amended Schedule 13G reporting its position in Tango Therapeutics, Inc. common stock. Woodline Partners, a Delaware limited partnership and investment adviser to two master funds, reports beneficial ownership of 4,000,567 shares of Tango common stock, with sole voting and dispositive power over all of these shares and no shared power. Based on an aggregate of 162,814,649 shares of Tango common stock outstanding, Woodline’s holdings represent approximately 2.5% of the class. The outstanding share figure reflects 18,166,667 shares offered under a June 10, 2026 prospectus plus 144,647,982 shares outstanding as of May 6, 2026.

Farallon Capital Management, L.L.C. and affiliated funds report beneficial ownership of Tango Therapeutics, Inc. common stock. The Farallon Funds together hold 12,277,000 Shares and 3,993,187 Pre-Funded Common Stock Purchase Warrants, each warrant exercisable for one Share, subject to a 9.99% Beneficial Ownership Limitation. Assuming all warrants are exercisable within 60 days, the Reporting Persons disclose beneficial ownership of 16,270,187 Shares, representing 9.8% of Tango’s outstanding common stock. Farallon Capital Management acts as investment manager to the Farallon Funds, and multiple individual managing members share voting and dispositive power over these securities.

Adage Capital Management, L.P. and related parties report beneficial ownership of Tango Therapeutics, Inc. common stock. Adage Capital Management, Robert Atchinson, and Phillip Gross collectively report beneficial ownership of 5,600,000 shares of common stock, representing 3.44% of the class. All 5,600,000 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive power. The percentage is based on 162,814,649 shares outstanding, consisting of 18,166,667 shares offered under a June 10, 2026 prospectus and 144,647,982 shares outstanding as of May 6, 2026. The filing indicates ownership of 5 percent or less of Tango’s common stock.

Tango Therapeutics, Inc. expanded its at-the-market offering program for its common stock through Leerink Partners LLC as sales agent. The company previously registered an aggregate offering price of up to $100,000,000 under a prior prospectus supplement, of which approximately $64,389,566 of shares have been sold and approximately $35,610,434 remain unsold.

On August 11, 2026, Tango filed a new prospectus supplement covering shares of common stock with an aggregate offering price of up to $400,000,000, which includes the approximately $35,610,434 of unsold shares from the prior prospectus supplement. The prior prospectus supplement has been terminated, and any future sales, if any, will be made under the new prospectus supplement and the existing automatic shelf registration statement. Goodwin Procter LLP issued a legal opinion on the newly registered shares.

Tango Therapeutics, Inc. is establishing a new at-the-market equity program to offer up to $400,000,000 of common stock through Leerink Partners as sales agent under its automatic shelf registration. Leerink may sell shares on Nasdaq Global Market, earning up to a 3.0% commission on gross sales.

The company previously had a $100,000,000 ATM under the same sales agreement and has already sold about $64.4 million, or 5,148,151 shares, which offering is now terminated. As of June 30, 2026, 168,380,091 shares were outstanding and net tangible book value was $1.025 billion, or $6.08 per share.

Illustratively, selling $400,000,000 of stock at $27.07 per share would increase net tangible book value to $1.416 billion, or $7.73 per share, implying dilution of $19.34 per share to new investors. Net proceeds are expected to fund working capital, operating expenses, and research and development, including manufacturing and clinical trial costs.

Tango Therapeutics, Inc. reported second-quarter 2026 results and provided clinical and corporate updates. Initial Phase 1/2 data showed vopimetostat plus daraxonrasib achieved a 92% objective response rate and 90% six-month progression-free survival in MTAP-deleted, RAS-mutant pancreatic cancer, with a generally well-tolerated safety profile. The company is working with regulators and collaborator Revolution Medicines on a registrational plan and intends to present detailed data at the 2026 ESMO Congress.

As of June 30, 2026, Tango held $1.0 billion in cash, cash equivalents and marketable securities. For the quarter, research and development expenses were $37.2 million and general and administrative expenses were $22.6 million, leading to a net loss of $55.3 million, or $0.37 per share. The company strengthened its leadership with the appointment of Fatma Ocak as Chief Commercialization Officer and Robert Azelby as Chairman of the Board, and outlined multiple clinical milestones expected in the second half of 2026.

Tango Therapeutics reported a larger net loss as it shifts from collaboration funding to equity capital while advancing its oncology pipeline. For the quarter ended June 30, 2026, net loss was $55.3 million versus $38.9 million a year earlier, with no collaboration revenue following the 2025 truncation of its Gilead research agreement.

Research and development expense rose to $37.2 million, driven by vopimetostat and TNG456 trials, while general and administrative expense nearly doubled to $22.6 million, largely from higher stock-based compensation. A June 2026 equity offering and at-the-market sales lifted cash, cash equivalents and marketable securities to about $1.0 billion, which the company expects will fund operations for at least 12 months.

Clinically, vopimetostat combinations showed encouraging early data in MTAP-deleted, RAS-mutant cancers, including high objective response and disease control rates in pancreatic and lung cohorts, and the company plans a Phase 3 trial in frontline pancreatic cancer. Tango is deprioritizing TNG260, TNG961 and has stopped new enrollment in TNG908 to focus resources on its PRMT5 franchise.